3[1]Jurcic D,Bago J,Eljuga D.Features of uremic neuropathy in longterm dialysis.Coll Antropol,1998,22( 1 ):119-125
4[2]Imam I,Salako BL,Akinola A.Peripheral neuropathy in Nigerian subjects with chronic renal failure.Niger J Med,2003,12(2):72-75
5[3]Man NK,Cueille G,Zingraff J,et al.Uremic neurotoxin in the middle molecular weight range.Artif Organs,1980,4(2):116-120
6[4]Dukanovic L.Middle molecular weight substances and uremic polyneuropathy.Acta Med Iugosl,1990,44(2):117-128
7[5]Avram MM,Feinfeld DA,Huatuco AH.Search for the uremic toxin.Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia.N Engl J Med,1978,298(18):1000-1003
8[6]Aiello I,Serra G,Gilli P,et al.Uremic neuropathy:correlations between electroneurographic parameters and serum levels of parathyroid hormone and aluminum.Eur Neurol,1982,21 (6):396-400
9[7]Barats MS,Gonick HC,Rothenberg S,et al.Severe lead-induced peripheral neuropathy in a dialysis patient.Am J Kidney Dis,2000,35(5):963-968
10[8]Cisari C,Gasco P,Calabrese G,et al.Serum magnesium and nerve conduction velocity in uraemic patients on chronic haemodialysis.Magnes Res,1989,2(4):267-269
1Martin K J, Gonzalez E A. Prevention and control of phosphate retention hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat[J].Clin J Am Soc Nephrol,2011,6(2):440-446.
2Gorriz J L, Molina P, Bover J ,et al. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: result of the OSERCE study[J]. Nerologia,2013,33(1):46-60.
